Evidence map›Paper›PMID 35214728›Full record

ArticleVaccines2022

Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C.

Juanjie Tang, Adrienne G Randolph, Tanya Novak, Tracie C Walker, Laura L Loftis, Matt S Zinter, Katherine Irby, Surender Khurana

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Juanjie TangCenter for Biologics Evaluation and Research (CBER), Division of Viral Products, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.
Adrienne G RandolphDepartment of Anesthesiology, Critical Care and Pain Medicine, Department of Anesthesia, Harvard Medical School, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-3084-3071
Tanya NovakDepartment of Anesthesiology, Critical Care and Pain Medicine, Department of Anesthesia, Harvard Medical School, Boston Children's Hospital, Boston, MA 02115, USA.
Tracie C WalkerDepartment of Pediatrics, University of North Carolina at Chapel Hill Children's Hospital, Chapel Hill, NC 27514, USA.
Laura L LoftisDepartment of Pediatrics, Division of Critical Care Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Matt S ZinterDepartment of Pediatrics, Divisions of Critical Care and Bone Marrow Transplantation, University of California, San Francisco, CA 94158, USA.
Katherine IrbyDepartment of Pediatrics, Division of Pediatric Critical Care Medicine, Arkansas Children's Hospital, Little Rock, AR 72202, USA.
Surender KhuranaCenter for Biologics Evaluation and Research (CBER), Division of Viral Products, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.
Boston Children's Hospital · USCenter for Biologics Evaluation and Research · USArkansas Children's Hospital · USBaylor College of Medicine · USUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · US

Funding

CDC HHS 75D30120C07725United States Food and Drug Administration Perinatal Health Center of Excellence (PHCE) project grant #GCBER005
6 · The paper itself

Abstract

Mucosal immunity plays an important role in the control of viral respiratory infections like SARS-CoV-2. While systemic immune responses against the SARS-2-CoV-2 have been studied in children, there is no information on mucosal antibody response, especially in the lower respiratory tract of children coronavirus disease 2019 (COVID-19) and post-infectious multisystem inflammatory syndrome in children (MIS-C) against emerging SARS-CoV-2 variants. Therefore, we evaluated neutralizing antibody responses in paired plasma and endotracheal aspirates of pediatric severe, acute COVID-19 or MIS-C patients against SARS-CoV-2 WA1/2020, as well as against variants of concern (VOCs). Neutralizing antibody responses against the SARS-CoV-2 WA1/2020 strain in pediatric plasma were 2-fold or 35-fold higher compared with the matched endotracheal aspirate in COVID-19 or MIS-C patients, respectively. In contrast to plasma, neutralizing antibody responses against the VOCs and variants of interest (VOIs) in endotracheal aspirates were lower, with only one endotracheal aspirate demonstrating neutralizing titers against the Iota, Kappa, Beta, Gamma, and Omicron variants. In conclusion, our findings suggest that children and adolescents with severe COVID-19 or MIS-C have weak mucosal neutralizing antibodies in the trachea against circulating SARS-CoV-2 Omicron and other VOCs, which may have implications for recovery and for re-infection with emerging SARS-CoV-2 variants.

Indexed as

COVID-19MIS-Cmucosal immunityneutralizationomicronpediatricSARS-CoV-2tracheavariants

Identifiers

PMID35214728
PMCPMC8879098
OpenAlexW4214683740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.